HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunotherapy in Alzheimer's disease: do we have all the pieces of the puzzle?

Abstract
Results of Phase III studies involving a large number of Alzheimer's disease (AD) patients treated by passive immunotherapy with humanized anti-amyloid β monoclonal antibodies have recently been released. These approaches failed to show a significant clinical benefit in patients with mild to moderate AD. The most considered explanation is that the patients have been treated too late. Whereas targeting patients at asymptomatic stages of the disease is a critical step in the goal of improving the efficacy of such antibody-based strategies, several other important factors should be considered in the development and clinical evaluation of anti-amyloid β immunotherapies, including the as yet poorly understood relationship of AD with the immune system and the importance of cerebral amyloid angiopathy. Better understanding the role of immune responses in AD and their impact on immunotherapy appears essential in the design of alternative or combinatorial immunotherapy approaches in AD, which may imply effectors other than antibodies and even additional antigenic targets.
AuthorsMarie Sarazin, Guillaume Dorothée, Leonardo Cruz de Souza, Pierre Aucouturier
JournalBiological psychiatry (Biol Psychiatry) Vol. 74 Issue 5 Pg. 329-32 (Sep 01 2013) ISSN: 1873-2402 [Electronic] United States
PMID23683656 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Amyloid beta-Peptides
Topics
  • Alzheimer Disease (therapy)
  • Amyloid beta-Peptides (immunology)
  • Humans
  • Immunotherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: